It has been estimated that each new episode of depression increases a patient's cumulative risk for relapse by 16% and those patients who have experienced three or more past depressions are at an elevated risk of staying chronically depressed (Solomon 2000). Patients with recurrent depression are, therefore, a logical group for targeted prevention efforts. To date, the best validated and most widely used approach for preventing relapse in recurrent depression is maintenance medication. However, the protection afforded lasts only as long as patients continue to take their medication. In light of this concern, there has been a growing interest in the use of treatments that combine recovery through medication with psychological prevention of relapse/recurrence (Fava et al., 1998). One such treatment is Mindfulness-Based Cognitive Therapy (MBCT), a group intervention designed to train recovered depressed patients to disengage from mood-linked depressive thinking styles that may trigger relapse/recurrence. While there are preliminary data on MBCT's preventative effects, we do not know how well this treatment fares in comparison with the most pervasive preventive intervention for depression, namely maintenance medication. We plan to identify a sample of 272 recurrently depressed outpatients and, during the acute treatment phase of this study, provide antidepressant medication. Remitted patients will then be randomly assigned to receive either maintenance medication, be withdrawn from medication and receive MBCT or be withdrawn and receive placebo and clinical management. All patients will then be followed for the next eighteen months. Our main hypotheses are that MBCT and maintenance medication will not differ in their efficacy, and that both will outperform placebo and clinical management. We will also perform analyses to examine a possible cognitive mechanism underlying MBCT's effectiveness as well as estimate the relative costs of MBCT compared to maintenance medication for prevention of relapse. Findings from this study would have clear public health significance because MBCT could prove to be an additional effective treatment for recurrently depressed patients who require maintenance courses of treatment to prevent relapse/recurrence. ? ?

Agency
National Institute of Health (NIH)
Institute
National Institute of Mental Health (NIMH)
Type
Research Project (R01)
Project #
1R01MH066992-01A2
Application #
6779441
Study Section
Special Emphasis Panel (ZMH1-CRB-U (01))
Program Officer
Pearson, Jane L
Project Start
2004-07-20
Project End
2009-04-30
Budget Start
2004-07-20
Budget End
2005-04-30
Support Year
1
Fiscal Year
2004
Total Cost
$446,631
Indirect Cost
Name
Centre for Addiction and Mental Health
Department
Type
DUNS #
207855271
City
Toronto
State
ON
Country
Canada
Zip Code
M5S2S-1
Farb, Norman A S; Segal, Zindel V; Anderson, Adam K (2013) Attentional modulation of primary interoceptive and exteroceptive cortices. Cereb Cortex 23:114-26
Bieling, Peter J; Hawley, Lance L; Bloch, Richard T et al. (2012) Treatment-specific changes in decentering following mindfulness-based cognitive therapy versus antidepressant medication or placebo for prevention of depressive relapse. J Consult Clin Psychol 80:365-72
Farb, Norman A S; Anderson, Adam K; Segal, Zindel V (2012) The mindful brain and emotion regulation in mood disorders. Can J Psychiatry 57:70-7
Farb, Norman A S; Anderson, Adam K; Bloch, Richard T et al. (2011) Mood-linked responses in medial prefrontal cortex predict relapse in patients with recurrent unipolar depression. Biol Psychiatry 70:366-72
Farb, Norman A S; Anderson, Adam K; Mayberg, Helen et al. (2010) Minding one's emotions: mindfulness training alters the neural expression of sadness. Emotion 10:25-33
Segal, Zindel V; Bieling, Peter; Young, Trevor et al. (2010) Antidepressant monotherapy vs sequential pharmacotherapy and mindfulness-based cognitive therapy, or placebo, for relapse prophylaxis in recurrent depression. Arch Gen Psychiatry 67:1256-64